Berg, a Boston-based biopharmaceutical company, will join an industry collaboration with Genomics England. Formed by British Prime Minister David Cameron, Genomics England is partnering with health companies to accomplish its mission to sequence 100,000 human genomes and create a new genomic medicine service for the National Health Services (NHS) by 2017. The project focuses on patients with rare diseases and six common cancers.

Through the GENE Consortium, Berg will work on an industry trial involving a selection of whole genome sequences across cancer and rare diseases, discovering how best to collaborate with clinicians and researchers. The trial aims to identify the most effective way of bringing industry expertise into the 100,000 Genomes Project in order to realize the potential benefits for patients.

Berg, the namesake of Chairman Carl Berg—who co-founded the company with Mitch Gray and Niven Narain, utilizes deep biological profiling and Bayesian artificial intelligence as a foundation to creating the next generation of drugs and diagnostics to improve human health.

Berg aims to use its expertise in data analytics, as well as its proprietary Interrogative Biology Platform, in the development of an analytical tool that will be used to process data from the 100,000 Genomes Project.